Loading...
Loading...
ADXN| Name | Value |
|---|---|
| Revenues | 53.8K |
| Cost of Revenue | 0.0K |
| Gross Profit | 53.8K |
| Operating Expense | 676.0K |
| Operating I/L | -622.2K |
| Other Income/Expense | -905.4K |
| Interest Income | 0.1K |
| Pretax | -1,527.6K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -1,530.0K |
Addex Therapeutics Ltd is a Swiss biopharmaceutical company specializing in the development and commercialization of small-molecule pharmaceutical products for central nervous system disorders. The company's primary focus is on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for Parkinson's disease levodopa-induced dyskinesia and dystonia, ADX71149 for epilepsy and undisclosed CNS disorders, and GABAB PAM for addiction. Addex Therapeutics has established license and collaboration agreements with Janssen Pharmaceuticals Inc., Indivior PLC, and The CharcotMarieTooth Association, driving its revenue through partnerships and product development.
